lusutrombopag   Click here for help

GtoPdb Ligand ID: 10032

Synonyms: Mulpleta® | S-888711 | S888711
Approved drug
lusutrombopag is an approved drug (Japan (2015), FDA (2018), EMA (2019))
Compound class: Synthetic organic
Comment: Lusutrombopag is an orally bioavailable, nonpeptidyl, small molecule thrombopoietin (TPO) receptor agonist [3] that was developed by Shionogi in Japan. It was the second TPO receptor agonist to receive FDA approval in 2018 (avatrombopag was the first).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 14
Topological polar surface area 125.99
Molecular weight 590.14
XLogP 7.78
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCCOC(c1cccc(c1OC)c1csc(n1)NC(=O)c1cc(Cl)c(c(c1)Cl)C=C(C(=O)O)C)C
Isomeric SMILES CCCCCCO[C@H](c1cccc(c1OC)c1csc(n1)NC(=O)c1cc(Cl)c(c(c1)Cl)/C=C(/C(=O)O)\C)C
InChI InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1
InChI Key NOZIJMHMKORZBA-KJCUYJGMSA-N
Bioactivity Comments
Lusutrombopag is selective for the human TPO receptor, and does not activate the mouse TPO receptor [3]. It promotes proliferation of Ba/F3-hMpl cells with an EC50 of 84 nM via activation of the same signal transduction pathways as native human TPO. Incubation of HuBM-CD34-positive cells with lusutrombopag for 12 days in vitro promotes megakaryocytic colony formation, which is indicative of enhanced platelet formation.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Thrombopoietin receptor Primary target of this compound Hs Agonist Agonist - - - 3
[3]